Biocytogen Pharmaceuticals (Beijing) (HKG:2315) said it expects to book up to 444% higher profit in 2025, according to a Hong Kong bourse filing Thursday.
The firm expects 162.4 million yuan to 182.4 million yuan in attributable profit for the year, 384% to 444% higher than the 33.5 million yuan posted in 2024.
Revenue is expected to rise 40% to 42% year on year to 1.34 billion yuan to 1.39 billion yuan.